摘要
目的系统评价儿童风湿热药物治疗循证指南的质量,比较推荐药物的异同,为临床使用提供参考。方法计算机检索TRIP、Pub Med、CNKI、VIP、Wan Fang、CBM及美国国家指南文库(U.S National Guideline Clearinghouse,NGC)、国际指南联盟(Guidelines International Network,G-I-N),纳入儿童风湿热药物治疗的循证指南,而后使用AGREEⅡ工具评价纳入指南的方法学质量,分析比较各指南推荐的异同。结果仅纳入1个循证临床指南,为澳大利亚指南。AGREEⅡ评价结果显示,在六大领域的评分中,范围和目的、利益相关者的参与情况、制定的严谨性、清晰性与可读性、适用性的得分均>50%,但编辑的独立性<50%。结论纳入的儿童风湿热药物治疗循证指南质量较好,但对于国内人群的适用性尚存在一定局限性,故制定国内高质量的儿童风湿热循证指南迫在眉睫。
Objective To systematically assess the quality of evidence-based clinical guidelines and to compare the differences and similarities between recommendations, so as to provide references for clinical application. Methods Databases such as the TRIP, PubMed, CNKI, VIP, WanFang Data, CBM, National Guideline Clearinghouse and Guidelines International Network were searched to collect evidence-based guidelines on medication therapy for children with rheumatic fever. Methodological quality of included guidelines was assessed according to the AGREE II instrument, and differences and similarities among recommendations were compared. Results Only one evidence-based clinical guideline from Australia was included. Among 6 domains which were rated using the AGREE II instrument, ＂scope and purpose＂, ＂stakeholder involvement＂, ＂rigor of development＂, ＂clarity and presentation＂ and ＂applicability＂ were scored more than 50%; while ＂editorial independence＂ was scored less than 50%. Conclusion The included guideline is of relatively high quality; however, its application among Chinese population still has limitations. Thus, the development of national guidelines is urgently needed.
出处
《中国循证医学杂志》
CSCD
2015年第1期23-27,共5页
Chinese Journal of Evidence-based Medicine
基金
INRUD中国中心组高风险用药人群药物管理组研究项目
关键词
儿童
风湿热
循证指南
系统评价
AGREEⅡ
Children
Rheumatic fever
Evidence-based guideline
Systematic review
AGREEⅡ
